May 23, 2014
1 min read
Save

Regeneron announces $626 million in 2014 first quarter revenue

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Regeneron reported total revenue of $626 million in the first quarter of 2014, a 42% increase from its 2013 first quarter revenue of $440 million, according to a press release.

Net product sales were reported at $362 million, increasing by $43 million from the first quarter of 2013.

The company reported $287 million in GAAP research and development expenses for the first quarter of 2014, marking an increase from $180 million during the same period in 2013. This difference was due to primarily increased research and development activities, including the antibody collaboration with Sanofi; higher research and development headcount; and higher non-cash shared-based compensation expense, the release said.

Non-GAAP net income was reported at $263 million, or $2.66 per basic share and $2.26 per diluted share, for the first quarter of 2014, compared with $201 million, or $2.07 per basic share and $1.78 per diluted share, for 2013. GAAP net income was $65 million, or $0.66 per basic share and $0.58 per diluted share, compared with $99 million, or $1.02 per basic share and $0.90 per diluted share, during the first quarter of 2013.